Copyright
©The Author(s) 2015.
World J Transplant. Dec 24, 2015; 5(4): 154-164
Published online Dec 24, 2015. doi: 10.5500/wjt.v5.i4.154
Published online Dec 24, 2015. doi: 10.5500/wjt.v5.i4.154
Table 1 Comparison of select preservation solutions
Euro-Collins | University of Wisconsin | Histidine-tryptophan-ketoglutarate | Celsior | |
Intracellular/extracellular | Intracellular | Intracellular | Extracellular | Extracellular |
Sodium | 10 | 25 | 15 | 100 |
Potassium | 115 | 120 | 10 | 15 |
Impermeant | Glucose | Lactobionate | Mannitol | Lactobionate |
Mannitol | Raffinose | Mannitol | ||
Hydroxyethyl starch | ||||
Buffer | Phosphate | Phosphate | Histidine | Histidine |
Bicarbonate | ||||
Antioxidant | Mannitol | Allopurinol | Tryptophan | Glutathione |
glutathione | Mannitol | Mannitol | ||
Histidine | Histidine | |||
Energy precursor | --- | Adenosine | Glutamic acid/glutamate | Glutamic acid/glutamate |
Others | Insulin | Ketoglutarate | ||
Dexamethasone |
Table 2 Selected clinical studies involving liver preservation solutions
Ref. | Solution | Cases | Patient survival | Graft survival |
UW vs HTK | ||||
Erhard et al[43] | UW vs HTK | 60 (UW 30, HTK 30) | No diff (30 mo) | No diff (3 mo) |
(UW 74%, HTK 77%) | (UW 80%, HTK 87%) | |||
Mangus et al[44] | UW vs HTK | 378 (UW 204, HTK 174) | No diff (1 yr) | No diff (1 yr) |
(UW 84.6%, HTK 82.1%) | (UW 81.7%, HTK 80.8%) | |||
Rayya et al[45] | UW vs HTK | 137 (UW 68, HTK 69) | No diff (1 yr) | No diff (1 yr) |
(UW 78%, HTK 78%) | (UW 78%, HTK 71%) | |||
Mangus et al[51] | UW vs HTK | 698 (UW 327, HTK 371) | No diff (1 yr) | No diff (1 yr) |
(UW 88%, HTK 87%) | (UW 84%, HTK 86%) | |||
Avolio et al[46] | UW vs HTK | 39 (UW 22, HTK 17) | No diff (not stated) | No diff (6 mo) |
(UW 82%, HTK 88%) | (UW 80.9%, HTK 85.7%) | |||
Canelo et al[47] | UW vs HTK | 134 (UW 71, HTK 63) | No diff | No diff |
Celsior vs (HTK or UW) | ||||
Nardo et al[57] | CEL vs HTK | 40 (CEL 20, HTK 20) | No diff (1 yr) | No diff (1 yr) |
(CEL 90%, HTK 85%) | (CEL 90%, HTK 75%) | |||
García-Gil et al[56] | CEL vs UW | 80 (CEL 40, UW 40) | No diff (1 yr) | No diff (1 yr) |
(CEL 85.7%, UW 79.8%) | (CEL 78%, UW 75.5%) | |||
Cavallari et al[55] | CEL vs UW | 173 (CEL 83, UW 90) | No diff (1 yr) | No diff (1 yr) |
(CEL 87%, UW 89%) | (CEL 85%, UW 83%) | |||
Lopez-Andujar et al[53] | CEL vs UW | 196 (CEL 92, UW 104) | No diff (1 yr) | No diff (1 yr) |
(CEL 83%, UW 83%) | (CEL 81%, UW 80%) | |||
Pedotti et al[54] | CEL vs UW | 175 (CEL 79, UW 96) | No diff (1 yr) | No diff (1 yr) |
(CEL 89.9%, UW 90.6%) | (CEL 83.3%, UW 85.4%) |
Table 3 Selected clinical studies involving renal preservation solutions
Ref. | Solution | Cases | Patient survival | Graft survival |
UW solution vs HTK solution | ||||
Lynch et al[60] | UW vs HTK | Living donor = 950 (UW 475, HTK 475) | No diff (1 yr) | No diff (1 yr) |
Deceased donor = 634 | (living or deceased donors) | (Living or deceased donors) | ||
(UW 317, HTK 317) | ||||
de Boer et al[61] | UW vs HTK | 611 (UW 297, HTK 314) | ---- | No diff (1 yr) |
(UW 81%, HTK 83%) | ||||
Klaus et al[62] | UW vs HTK | 51 (UW 27, HTK 24) | No diff (1 yr) | No diff (1 yr) |
(UW 84% vs HTK 86%) | (UW 78%, HTK 79%) | |||
UW solution vs CEL solution | ||||
Montalti et al[64] | UW vs CEL | 50 (UW 25, CEL 25) | No diff (1 yr) | No diff (1 yr) |
(UW 100%, CEL 100%) | (UW 96%, CEL 91.8%) | |||
P value not stated | ||||
Faenza et al[23] | UW vs CEL | 187 (UW 88, CEL 99) | No diff (2 yr) | No diff (2 yr) |
(UW 100%, CEL 100%) | (UW 75%, CEL 84%) | |||
P value not stated | ||||
Pedotti et al[54] | UW vs CEL | 441 (UW 269, CEL 172) | No diff (1 yr) | No diff (1 yr) |
(UW 97.7%, CEL 99.4%) | (UW 91%, CEL 94.2%) | |||
P value not stated | P value not stated | |||
EC solution vs HTK solutions | ||||
de Boer et al[61] | EC vs HTK | 569 (EC 277, HTK 292) | ---- | No diff (1 yr) |
(EC 78%, HTK 80%) | ||||
P value not stated |
Table 4 Selected clinical studies involving pancreas preservation solutions
Ref. | Solution | Cases | Patient survival | Graft survival |
UW solution vs HTK solution | ||||
Potdar et al[68] | UW vs HTK | 33 (UW 17, HTK 16) | No diff (30 d) | No diff (30 d) |
(UW 100%, HTK 100%) | (UW 100%, HTK 94%) | |||
Englesbe et al[69] | UW vs HTK | 75 (UW 41, HTK 36) | No diff (90 d) | No diff (90 d) |
(UW 100%, HTK 100%) | (UW 90.2%, HTK 86%) | |||
Schneeberger et al[70] | UW vs HTK | 68 (UW 41, HTK 27) | No diff (6 mo) | No diff (6 mo) |
(100% UW and HTK 96.3%) | (90.2% UW, 85.2% HTK) | |||
Becker et al[71] | UW vs HTK | 95 (UW 47, HTK 48) | No diff (1 yr) | No diff (1 yr) |
(UW 89.4% and HTK 95.7%) | (UW 82.6%, HTK 85.4%) | |||
Agarwal et al[72] | UW vs HTK | 87 (UW 10, HTK 78) | No diff (1 yr) | No diff (1 yr) |
(UW 100% and HTK 93%) | (UW 100% and HTK 92%) | |||
Alonso et al[74] | UW vs HTK | 97 (UW 81, HTK 16) | No diff (3 yr) | No diff (3 yr) |
UW solution vs CEL solution | ||||
Manrique et al[77] | UW vs CEL | 72 (UW 44, HTK 28) | No diff (2 yr) | No diff (2 yr) |
(UW 94.7%, CEL 84.4%) | (UW 74.6%, CEL 77.4%) | |||
Boggi et al[25] | UW vs CEL | 100 (UW 50, HTK 50) | No diff (1 yr) | No diff (1 yr) |
(UW 98.0%, CEL 98.0%) | (UW 95.8%, CEL 95.9%) |
- Citation: Latchana N, Peck JR, Whitson BA, Henry ML, Elkhammas EA, Black SM. Preservation solutions used during abdominal transplantation: Current status and outcomes. World J Transplant 2015; 5(4): 154-164
- URL: https://www.wjgnet.com/2220-3230/full/v5/i4/154.htm
- DOI: https://dx.doi.org/10.5500/wjt.v5.i4.154